Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oruka Therapeutics, Inc. - Common Stock
(NQ:
ORKA
)
30.18
-0.03 (-0.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oruka Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Oruka Therapeutics to Present at Multiple March Investor Conferences
February 19, 2025
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 05, 2025
Via
Benzinga
Discover the top movers in Tuesday's pre-market session.
↗
February 04, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
February 04, 2025
Via
Benzinga
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
February 04, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 04, 2025
Via
Benzinga
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
January 15, 2025
Via
Benzinga
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket
↗
January 15, 2025
Via
Benzinga
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
December 19, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
December 18, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
November 19, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics to Present at Multiple November Investor Conferences
November 04, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
↗
October 08, 2024
Via
Benzinga
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
September 25, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Announces $200 Million Private Placement
September 12, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 12, 2024
From
Oruka Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today